Search

Your search keyword '"Merante S"' showing total 142 results
Start Over Author "Merante S"
142 results on '"Merante S"'

1. SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis

Author

Martinelli, G, Mancini, M, De Benedittis, C, Rondoni, M, Papayannidis, C, Manfrini, M, Meggendorfer, M, Calogero, R, Guadagnuolo, V, Fontana, M C, Bavaro, L, Padella, A, Zago, E, Pagano, L, Zanotti, R, Scaffidi, L, Specchia, G, Albano, F, Merante, S, Elena, C, Savini, P, Gangemi, D, Tosi, P, Ciceri, F, Poletti, G, Riccioni, L, Morigi, F, Delledonne, M, Haferlach, T, Cavo, M, Valent, P, and Soverini, S

Published
2018
Full Text
View/download PDF

6. Conut score as a tool for early detection of poor nutritional status in advances forms of SM

Author

Gruchala-Niedoszytko, M., Gorska, A., Nedoszytko, B., Lange, M., Niedoszytko, M., Rabenhorst, A., Sperr, W., Elberink, Oude J., Gleixner, K., Brazzelli, V., Fontana, E., Vos, B., Reiter, A., Schwaab, J., Zanotti, R., Bonadonna, P., Triggiani, M., Gotlib, J., Doubek, M., Jakob, T., Fuchs, D., Sabato, V., Bretterklieber, A., Jaekel, N., Sotlar, K., Horny, H., Fortina, Belloni A., Merante, S., Kluin-Nelemans, H., Hartmann, K., Valent, P., and Arock, M.

Published
2019

9. Achieving a Major Molecular Response at the Time of a Complete Cytogenetic Response (CCgR) Predicts a Better Duration of CCgR in Imatinib-Treated Chronic Myeloid Leukemia Patients

Author

Iacobucci, I, Saglio, Giuseppe, Rosti, G, Testoni, N, Pane, F, Amabile, M, Poerio, A, Soverini, S, Bassi, S, Cilloni, Daniela, Bassan, R, Breccia, M, Lauria, F, Izzo, B, Merante, S, Frassoni, F, Paolini, S, Montefusco, E, Baccarani, M, Martinelli, G, Gimema, Working, PARTY ON CHRONIC MYELOID LEUKEMIA, Iacobucci, I, Saglio, G, Rosti, G, Testoni, N, Pane, Fabrizio, Amabile, M, Poerio, A, Soverini, S, Bassi, S, Cilloni, D, Bassan, R, Breccia, M, Lauria, F, Izzo, Barbara, Merante, S, Frassoni, F, Paolini, S, Montefusco, E, Baccarani, M, Martinelli, G., Iacobucci I, Saglio G, Rosti G, Testoni N, Pane F, Amabile M, Poerio A, Soverini S, Bassi S, Cilloni D, Bassan R, Breccia M, Lauria F, Izzo B, Merante S, Frassoni F, Paolini S, Montefusco E, Baccarani M, and Martinelli G

Subjects
Male, Oncology, Cancer Research, Neoplasm, Residual, Time Factors, Piperazines, hemic and lymphatic diseases, Chronic, CML, MOLECULAR RESPONSE, Leukemia, Reverse Transcriptase Polymerase Chain Reaction, Remission Induction, CHRONIC MYELOGENOUS LEUKEMIA, Myeloid leukemia, Middle Aged, Prognosis, MINIMAL-RESIDUAL-DISEASE, INTERFERON-ALPHA THERAPY, FUSION GENE TRANSCRIPTS, CHRONIC-PHASE, REMISSION, CYTARABINE, SURVIVAL, MESYLATE, Treatment Outcome, Residual, Predictive value of tests, Benzamides, Imatinib Mesylate, Female, medicine.drug, Adult, medicine.medical_specialty, Endpoint Determination, Antineoplastic Agents, Genes, abl, IMATINIB, Myelogenous, Predictive Value of Tests, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Internal medicine, medicine, Humans, neoplasms, CYTOGENETIC RESPONSE, Aged, CHRONIC MYELOID LEUKEMIA, business.industry, abl, Cytogenetics, Imatinib, medicine.disease, Clinical trial, Pyrimidines, Imatinib mesylate, Genes, Immunology, Neoplasm, BCR-ABL Positive, beta 2-Microglobulin, business
Abstract

Purpose: Most patients with chronic-phase chronic myeloid leukemia (CML) who receive imatinib achieve a complete cytogenetic remission (CCgR) and low levels of BCR-ABL transcripts. CCgR is durable in the majority of patients but relapse occurs in a subset. Experimental Design: To determine the potential of quantitative reverse transcription-PCR of BCR-ABL to predict cytogenetic relapse, we serially monitored residual disease in 97 CML patients with an imatinib-induced CCgR. Patients with late chronic phase CML after IFN-α failure were treated with imatinib (400 mg daily). Results: During the imatinib median follow-up time of 36 months (range, 12-54 months), disease monitoring occurred by cytogenetics and quantitative PCR. Twenty percent of patients experienced cytogenetic relapse at a median of 18 months after CCgR and a median of 24 months after starting imatinib. None of the possible prognostic factors studied in univariate and multivariate analyses seemed to predict for loss of cytogenetic response but the reduction of BCR-ABL transcript levels at the time of CCgR is an important prognostic factor. Conclusions: In our study, we showed not only that achieving a major molecular remission at 12 months is predictive of a durable cytogenetic remission but also that patients who achieved a major molecular remission (expressed both as the BCR-ABL/β2 microglobulin ratio %

Published
2006

10. Ultra-deep sequencing (uds) allows more sensitive detection of the D816V and other kit gene mutations in systemic mastocytosis

Author

Benedittis, C., Soverini, S., CRISTINA PAPAYANNIDIS, Rondoni, M., Colarossi, S., Dal Pero, F., Zanotti, R., Matteis, G., Mancini, M., Zazzeroni, L., Elena, C., Merante, S., Grifoni, F. I., Bonifacio, M., Perbellini, O., Specchia, G., Pagano, L., Gangemi, D., Bonadonna, P., Pieri, L., Cavo, M., Martinelli, G., and De Benedittis C, Soverini S, Papayannidis C, Rondoni M, Colarossi S, Dal Pero F, Zanotti R, De Matteis G, Mancini M, Zazzeroni L, Elena C, Merante S, Grifoni FI, Bonifacio M, Perbellini O, Specchia G, Pagano L, Gangemi D, Bonadonna P, Pieri L, Cavo M, Martinelli G

Subjects
D816V mutation, somatic autoactivating point mutation, bone marrow, KIT receptor gene, Indolent Systemic Mastocytosi, Systemic Mastocytosi, ultra-deep amplicon sequencing, Systemic Mastocytosis, Systemic Mastocytosis, KIT mutations, UDS, D816V detection, KIT mutations, UDS
Published
2015

12. Age at disease onset has a major impact on clinical characteristics and course of mastocytosis

Author

Rabenhorst, A., Sperr, W., Elberink, J. Oude, Lange, M., Gleixner, K., Brazzelli, V., Fontana, E., Vos, B., Gorska, A., Reiter, A., Schwaab, J., Zanotti, R., Bonadonna, P., Triggiani, M., Gotlib, J., Doubek, M., Jakob, T., Kilbertus, A., Sabato, V., Zink, A., Bretterklieber, A., Jaekel, N., Sotlar, K., Horny, H., Fortina, A. Belloni, Merante, S., Niedoszytko, M., Kluin-Nelemans, H., Valent, P., Hartmann, K., Rabenhorst, A., Sperr, W., Elberink, J. Oude, Lange, M., Gleixner, K., Brazzelli, V., Fontana, E., Vos, B., Gorska, A., Reiter, A., Schwaab, J., Zanotti, R., Bonadonna, P., Triggiani, M., Gotlib, J., Doubek, M., Jakob, T., Kilbertus, A., Sabato, V., Zink, A., Bretterklieber, A., Jaekel, N., Sotlar, K., Horny, H., Fortina, A. Belloni, Merante, S., Niedoszytko, M., Kluin-Nelemans, H., Valent, P., and Hartmann, K.

Published
2017

13. Impact of allergic disorders and anaphylaxis in mastocytosis: Preliminary data from a study of the European Competence Network on Mastocytosis (ECNM) registry

Author

Niedoszytko, M., Gorska, A., Nedoszytko, B., Rabenhorst, A., Sperr, W., Elberink, Oude J., Lange, M., Gleixner, K., Brazzelli, V, Fontana, E., Vos, B., Reiter, A., Schwaab, J., Zanotti, R., Bonadonna, P., Triggiani, M., Gotlib, J., Doubek, M., Jakob, T., Fuchs, D., Sabato, V, Zink, A., Bretterklieber, A., Jaekel, N., Sotlar, K., Horny, H., Fortina, Belloni A., Merante, S., Kluin-Nelemans, H., Valent, P., Hartmann, K., Niedoszytko, M., Gorska, A., Nedoszytko, B., Rabenhorst, A., Sperr, W., Elberink, Oude J., Lange, M., Gleixner, K., Brazzelli, V, Fontana, E., Vos, B., Reiter, A., Schwaab, J., Zanotti, R., Bonadonna, P., Triggiani, M., Gotlib, J., Doubek, M., Jakob, T., Fuchs, D., Sabato, V, Zink, A., Bretterklieber, A., Jaekel, N., Sotlar, K., Horny, H., Fortina, Belloni A., Merante, S., Kluin-Nelemans, H., Valent, P., and Hartmann, K.

Published
2017

14. The body mass index is an indicator of advanced systemic mastocytosis: preliminary results from a registry project of the European Competence Network on Mastocytosis (ECNM) registry

Author

Gorska, A., Gruchala-Niedoszytko, M., Niedoszytko, M., Rabenhorst, A., Sperr, W., Elberink, Oude J., Lange, M., Gleixner, K., Brazzelli, V, Fontana, E., Vos, B., Reiter, A., Schwaab, J., Zanotti, R., Bonadonna, P., Triggiani, M., Gotlib, J., Doubek, M., Jakob, T., Fuchs, D., Sabato, V, Zink, A., Bretterklieber, A., Jaekel, N., Sotlar, K., Horny, H., Fortina, Belloni A., Merante, S., Kluin-Nelemans, H., Valent, P., Hartmann, K., Gorska, A., Gruchala-Niedoszytko, M., Niedoszytko, M., Rabenhorst, A., Sperr, W., Elberink, Oude J., Lange, M., Gleixner, K., Brazzelli, V, Fontana, E., Vos, B., Reiter, A., Schwaab, J., Zanotti, R., Bonadonna, P., Triggiani, M., Gotlib, J., Doubek, M., Jakob, T., Fuchs, D., Sabato, V, Zink, A., Bretterklieber, A., Jaekel, N., Sotlar, K., Horny, H., Fortina, Belloni A., Merante, S., Kluin-Nelemans, H., Valent, P., and Hartmann, K.

Published
2017

15. Long term outcome of ph+ cml patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era

Author

Malagola M, Breccia M, Skert C, Cancelli V, Cattina F, Liberati AM, Tiribelli M, Annunziata M, Trabacchi E, De Vivo A, Fogli M, Stagno F, Pica G, Iurlo A, Pregno P, Abruzzese E, Pardini S, Bocchia M, Russo S, Pierri I, Lunghi M, Barulli S, Merante S, Mandelli F, Alimena G, Russo D., SOVERINI, SIMONA, IACOBUCCI, ILARIA, CASTAGNETTI, FAUSTO, MARTINELLI, GIOVANNI, ROSTI, GIANANTONIO, BACCARANI, MICHELE, Malagola M, Breccia M, Skert C, Cancelli V, Soverini S, Iacobucci I, Cattina F, Liberati AM, Tiribelli M, Annunziata M, Trabacchi E, De Vivo A, Castagnetti F, Martinelli G, Fogli M, Stagno F, Pica G, Iurlo A, Pregno P, Abruzzese E, Pardini S, Bocchia M, Russo S, Pierri I, Lunghi M, Barulli S, Merante S, Mandelli F, Alimena G, Rosti G, Baccarani M, and Russo D.

Subjects
Adult, Male, EUROPE, Fusion Proteins, bcr-abl, MULTICENTER, Antineoplastic Agents, Piperazines, RECOMMENDATIONS, Young Adult, CHRONIC MYELOID-LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA, MOLECULAR RESPONSE, RESIDUAL DISEASE, T-LYMPHOCYTES, ALPHA, TRANSCRIPTS, INTERFERON THERAPY, hemic and lymphatic diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Antineoplastic Combined Chemotherapy Protocols, Humans, BCR-ABL, Protein Kinase Inhibitors, Aged, Retrospective Studies, Drug Substitution, Remission Induction, Interferon-alpha, Middle Aged, Cross-Sectional Studies, Pyrimidines, Treatment Outcome, Benzamides, Imatinib Mesylate, Female, CHRONIC MYELOID LEUKEMIA (CML), Follow-Up Studies
Abstract

Interferon α (IFNα) prolongs survival of CML patients achieving CCyR and potentially synergizes with TKIs. We report on the molecular status and long term outcome of 121 patients who were treated in Italy between 1986 and 2000 with IFNα based therapy and who obtained CCyR. After a median follow up of 16.5 years, 74 (61%) patients were switched to standard imatinib: 48 (65%) lost the CCyR on IFNα, and 36 (75%) are alive and in CCyR; 26 (35%) were switched to imatinib when they were still in CCyR on IFNα, and all 26 are alive and in CCyR. Forty-seven patients (39%) were never switched to imatinib: 24 (51%) continued and 23 (49%) discontinued IFNα, respectively, and 39/47 (83%) are alive and in CCyR. At last follow-up, the BCR-ABL transcripts level was available in 96/101 living patients (95%) The BCR-ABL:ABL ratio was between 0.1 and 0.01% (MR(3.0) ) in 17%, and less than 0.01% (MR(4.0) ) in 81% of patients. No patient was completely molecular negative (MR(4.5) or MR(5.0) ). The OS at 10 and 20 years is 92 and 84%, respectively. This study confirms that CCyR achieved with IFNα and maintained with or without imatinib or any other therapy significantly correlates with long term survival in CML patients who mostly have MR(4.0) . Complete molecular response (MR(4.5) or MR(5.0) ) seems to be unnecessary for such a long survival. This study further supports development of studies testing the clinical effect of the combinations of TKIs with IFNα.

Published
2014

16. SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis

Author

Martinelli, G, primary, Mancini, M, additional, De Benedittis, C, additional, Rondoni, M, additional, Papayannidis, C, additional, Manfrini, M, additional, Meggendorfer, M, additional, Calogero, R, additional, Guadagnuolo, V, additional, Fontana, M C, additional, Bavaro, L, additional, Padella, A, additional, Zago, E, additional, Pagano, L, additional, Zanotti, R, additional, Scaffidi, L, additional, Specchia, G, additional, Albano, F, additional, Merante, S, additional, Elena, C, additional, Savini, P, additional, Gangemi, D, additional, Tosi, P, additional, Ciceri, F, additional, Poletti, G, additional, Riccioni, L, additional, Morigi, F, additional, Delledonne, M, additional, Haferlach, T, additional, Cavo, M, additional, Valent, P, additional, and Soverini, S, additional

Published
2017
Full Text
View/download PDF

17. THE ITALIAN MASTOCYTOSIS REGISTRY: THE FIRST FIVE YEARS

Author

Merante, S., Neri, I., Magliacane, D., Fortina, A. Belloni, Ingeborg, F., Pastorello, E. A., Mauro, M., Minelli, R., Difonzo, E. D. Elisa, Guggiari, E., Peserico, A., Romani, I., Bocchia, M., Fontana, E., Di Nuzzo, S., Elli, E. M., Elena, C., Virginia Valeria Ferretti, Brazzelli, V., Ciccocioppo, R., Di Stefano, M., Bossi, G., Boveri, E., Virdi, A., and Triggiani, M.

Published
2015

18. Bcr-Abl kinase domain mutations and resistance in Ph+ acute lymphoblastic leukemia from the imatinib to the 2nd-generation TKI era

Author

SOVERINI, SIMONA, DE BENEDITTIS, CATERINA, IACOBUCCI, ILARIA, VENTURI, CLAUDIA, PAPAYANNIDIS, CRISTINA, MALAGOLA, MICHELE, BACCARANI, MICHELE, MARTINELLI, GIOVANNI, GNANI A., LUPPI M., MERANTE S., RUSSO D., TIRIBELLI M., SALVUCCI M., VITALE A., ELIA L., VIGNETTI M., FOÀ R., SOVERINI S., GNANI A., CATERINA DE BENEDITTIS C., IACOBUCCI I., VENTURI C., PAPAYANNIDIS C., LUPPI M., MERANTE S., MALAGOLA M., RUSSO D., TIRIBELLI M., SALVUCCI M., VITALE A., ELIA L., VIGNETTI M., FOÀ R., BACCARANI M., and MARTINELLI G.

Subjects
TYROSINE KINASE INHIBITORS
Published
2012

19. FOLLOW UP A LUNGO TERMINE DEI PAZIENTI CON LMC-PH+ IN RISPOSTA CITOGENETICA COMPLETA CON TERAPIA INCLUDENTE INTERFERONE NELL’ERA IMATINIB - PROTOCOLLO GIMEMA CML0509

Author

Russo, D, Alimena, G, Colombi, C, Breccia, M, Soverini, S, Iacobucci, I, Cattina, F, Martinelli, G, Testoni, N, Liberati, Am, Appolloni, V, Tiribelli, M, Fanin, R, Ferrara, F, Annunziata, M, Trabacchi, E, Vallisa, D, De Vivo, A, Castagnetti, F, Fogli, M, Durante, S, Di Raimondo, F, Stagno, F, Carella, Am, Pica, G, Cortelezzi, A, Iurlo, A, Pregno, P, Vitolo, U, Abruzzese, E, De Fabritiis, P, Longinotti, M, Pardini, S, Musolino, C, Russo, S, Gobbi, M, Pierri, I, Gaidano, G, Lunghi, M, Visani, G, Barulli, S, Cazzola, M, Merante, S, Skert, C, Malagola, M, Rosti, G, Mandelli, F, and Baccarani, M

Published
2012

20. BCR-ABL KINASE DOMAIN MUTATIONS IN IMATINIB AND IN SECOND- GENERATION TYROSINE KINASE INHIBITOR ERAS: A REVIEW OF SEVEN YEARS OF MUTATION ANALYSIS BY THE GIMEMA CML WORKING PARTY

Author

Soverini, S, Gnani, A, De Benedittis, C, Castagnetti, F, Gugliotta, G, Breccia, M, Abruzzese, E, Sorà, F, Pregno, P, Baratè, C, Orlandi, E, Merante, S, Gangemi, D, Specchia, G, Capucci, A, Russo, D, Giannini, B, Iacobucci, I, Amabile, M, Bochicchio, Mt, Palandri, F, Pane, F, Saglio, G, Rosti, G, Baccarani, M, and Martinelli, G

Published
2011

24. Prediction response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients. Study by the GIMEMA working party on chronic myeloid leukemia

Author

Martinelli, G., Iacobucci, I., Rosto, G., Pane, F., Amabile, M., Castagnetti, F., Cilloni, D., Soverini, S., Testoni, N., Specchia, G., Merante, S., Zaccaria, A., Frassoni, F., Saglio, G., Baccarani, M., GIMEMA working party, and Liberati, Anna Marina

Subjects
chronic myeloid leukemia KeyWords Plus:CHRONIC MYELOGENOUS LEUKEMIA, CML PATIENTS, late-chronic phase, POLYMERASE-CHAIN-REACTION, RESIDUAL DISEASE, Author Keywords:imatinib mesylate, COMPLETE CYTOGENETIC RESPONDERS, INTERFERON-ALPHA, FOLLOW-UP, MESYLATE, REMISSION, THERAPY
Published
2006

30. Idiopathic hypereosinphilic synndrome (HES) with FIP1L1-PDGFR-alpha rearrangement can be effectively treated with imatinib

Author

Martinelli, G, Cilloni, D, Ottaviani, E, Malagola, Michele, Messa, F, Rondoni, M, Bosi, C, Gottardi, E, Rosti, G, Ricci, P, Gaitani, S, Pane, F, Testoni, N, Mecucci, C, Soverini, S, Piccaluga, Pp, Amabile, M, Tiribelli, M, Zaccaria, A, Grafone, T, De Vivo, A, Pileri, S, Fattori, Pp, Bocchia, M, Serra, A, Maurillo, L, Fanin, R, Cross, N, Merante, S, Cazzola, M, Alimena, G, Frassoni, F, Galieni, P, Russo, Domenico, Gobbi, M, Gugliotta, L, Lauria, F, Mazza, P, Ferrara, F, Gherlinzoni, F, Leoni, P, Pellegrino, M, Baccarani, M, and Saglio, G.

Published
2004

32. European multicenter experience on idiopathic hypereosynophilic syndrome with FIP1L1-PDGFR-alpha rearrangement treated with imatinib

Author

Martinelli, G, Apperley, J, Reiter, A, Cross, N, Cilloni, D, Grimwade, D, Hochaus, A, Ottaviani, E, Cools, J, Prin, L, Malagola, Michele, Walz, C, Preudhomme, C, Messa, F, Rondoni, M, Gottardi, E, Rosti, G, Mecucci, C, Pane, F, Testoni, N, Soverini, S, Merante, S, Alimena, G, Baccarani, M, Hehlman, R, Aventin, A, Sureda, A, Gomez, Jr, Duyster, J, Verhoef, G, and Saglio, G.

Published
2004

33. Italian Cooperative study on idiopathic hypereosinophilic syndrome (HES): FIP1-L1/PDGFRA rearrangement can be effectively treated with Imatinib

Author

Martinelli, G, Cilloni, D, Ottavini, E, Malagola, Michele, Cross, N, Rosti, G, Gaitani, S, Pane, F, Giannini, B, Testoni, N, Mecucci, C, Soverini, S, Piccaluga, Pp, Rondoni, M, Amabile, M, Tiribelli, M, Bosi, C, Poerio, A, Zuffa, E, Zaccaria, A, Grafone, T, De Vivo, A, Ascani, S, Pileri, S, Visani, G, Fattori, P, Bocchia, M, Serra, A, Gottardi, E, Maurillo, L, Merante, S, Cazzola, M, Fanin, R, Saglio, G, Bertieri, R, and Baccarani, M.

Published
2003

40. Evolving approaches with alpha interferon in chronic myelogenous leukemia

Author

Morra, E, Alimena, G, Lazzarino, M, Liberati, Anna Marina, Montefusco, E, Bernasconi, P, Mancini, M, Donti, E, Merante, S, and Caricchi, P.

Subjects
Myeloid, Leukemia, eMTREE drug terms: alpha2b interferon, Philadelphia-Positive, adult, philadelphia 1 chromosome, leukemia remission, Cytarabine, Interferon Alfa-2b, subcutaneous drug administration MeSH: Adult, major clinical study, drug efficacy, aged, mosaicism, Treatment Outcome, priority journal, chronic myeloid leukemia, Antineoplastic Combined Chemotherapy Protocols, Hydroxyurea, human, hydroxyurea EMTREE medical terms: adolescent, conference paper, cytarabine, Human, Leukemia, Myeloid, Philadelphia-Positive
Published
1993

41. Risk assessment in myelodysplastic syndromes: Value of clinical, hematologic and bone marrow histologic findings at presentation

Author

Morra, E., primary, Lazzarino, M., additional, Castello, A., additional, Inverardi, D., additional, Coci, A., additional, Alessandrino, E. P., additional, Brusamolino, E., additional, Bernasconi, P., additional, Orlandi, E., additional, Bonfichi, M., additional, Merante, S., additional, Zei, G., additional, and Bernasconi, C., additional

Published
2009
Full Text
View/download PDF

42. The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up

Author

Palandri, F., primary, Castagnetti, F., additional, Alimena, G., additional, Testoni, N., additional, Breccia, M., additional, Luatti, S., additional, Rege-Cambrin, G., additional, Stagno, F., additional, Specchia, G., additional, Martino, B., additional, Levato, L., additional, Merante, S., additional, Liberati, A. M., additional, Pane, F., additional, Saglio, G., additional, Alberti, D., additional, Martinelli, G., additional, Baccarani, M., additional, and Rosti, G., additional

Published
2009
Full Text
View/download PDF

43. Response to imatinib mesylate in patients with the FIP1L1-PDGFR-alpha positive hypereosinophilic syndrome: Update of a multicenter prospective study and guidelines for eosinophilia diagnosis

Author

Merante, S., primary, Rondoni, M., additional, Otaviani, E., additional, Paolini, S., additional, Cilloni, D., additional, Messa, F., additional, Iannitto, E., additional, Pane, F., additional, Saglio, G., additional, Martinelli, G., additional, and Baccarani, M., additional

Published
2008
Full Text
View/download PDF

44. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFR -positive hypereosinophilic syndrome. Results of a multicenter prospective study

Author

Baccarani, M., primary, Cilloni, D., additional, Rondoni, M., additional, Ottaviani, E., additional, Messa, F., additional, Merante, S., additional, Tiribelli, M., additional, Buccisano, F., additional, Testoni, N., additional, Gottardi, E., additional, de Vivo, A., additional, Giugliano, E., additional, Iacobucci, I., additional, Paolini, S., additional, Soverini, S., additional, Rosti, G., additional, Rancati, F., additional, Astolfi, C., additional, Pane, F., additional, Saglio, G., additional, and Martinelli, G., additional

Published
2007
Full Text
View/download PDF

49. Treatment of terminal‐phase chronic myelogenous leukemia with intermediate‐dose cytarabine and hydroxyurea

Author

Lazzarino, M., primary, Morra, E., additional, Brusamolino, E., additional, Alessandrino, E. P., additional, Orlandi, E., additional, Pagnucco, G., additional, Castagnola, C., additional, Bernasconi, P., additional, Merante, S., additional, Bonfichi, M., additional, Castelli, G., additional, Canevari, A., additional, and Bernasconi, C., additional

Published
1991
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results